Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CONMED Corporation stock logo
CNMD
CONMED
$52.01
-0.6%
$55.18
$46.00
$78.19
$1.61B1.24443,723 shs1.21 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$18.00
+5.3%
$17.66
$14.17
$34.13
$2.01B0.741.13 million shs3.33 million shs
Westaim Corp. stock logo
WEDXF
Westaim
$22.59
+0.2%
$23.00
$16.62
$25.98
$758.12M0.242,963 shs500 shs
Warby Parker Inc. stock logo
WRBY
Warby Parker
$21.89
+1.9%
$19.25
$12.46
$28.68
$2.29B2.11.97 million shs3.22 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CONMED Corporation stock logo
CNMD
CONMED
0.00%-0.36%-8.38%-14.18%-24.97%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+7.85%-4.61%+1.01%+5.08%
Westaim Corp. stock logo
WEDXF
Westaim
0.00%-0.88%-3.87%+2.92%+660.61%
Warby Parker Inc. stock logo
WRBY
Warby Parker
0.00%+0.82%+3.26%+19.99%+36.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CONMED Corporation stock logo
CNMD
CONMED
4.5777 of 5 stars
2.13.02.54.32.20.83.1
NovoCure Limited stock logo
NVCR
NovoCure
3.7591 of 5 stars
3.31.00.04.53.11.70.0
Westaim Corp. stock logo
WEDXF
Westaim
0.267 of 5 stars
0.04.00.00.00.00.00.6
Warby Parker Inc. stock logo
WRBY
Warby Parker
1.8955 of 5 stars
2.33.00.00.01.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CONMED Corporation stock logo
CNMD
CONMED
2.20
Hold$62.2019.59% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.67
Moderate Buy$32.8382.41% Upside
Westaim Corp. stock logo
WEDXF
Westaim
0.00
N/AN/AN/A
Warby Parker Inc. stock logo
WRBY
Warby Parker
2.61
Moderate Buy$22.884.49% Upside

Current Analyst Ratings Breakdown

Latest WEDXF, NVCR, CNMD, and WRBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/12/2025
CONMED Corporation stock logo
CNMD
CONMED
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$61.00
5/29/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.00
5/22/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.00
5/21/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/21/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/21/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.00
5/21/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$18.00 ➝ $21.00
5/21/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $24.00
5/13/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.00
5/9/2025
Warby Parker Inc. stock logo
WRBY
Warby Parker
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $20.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CONMED Corporation stock logo
CNMD
CONMED
$1.31B1.23$6.69 per share7.77$31.16 per share1.67
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.32N/AN/A$3.33 per share5.41
Westaim Corp. stock logo
WEDXF
Westaim
$17.04M44.49N/AN/A$23.28 per share0.97
Warby Parker Inc. stock logo
WRBY
Warby Parker
$771.32M2.97$0.34 per share64.48$3.35 per share6.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CONMED Corporation stock logo
CNMD
CONMED
$132.42M$3.8013.6910.261.349.02%14.36%5.86%7/30/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)
Westaim Corp. stock logo
WEDXF
Westaim
-$16.18M-$2.17N/AN/A-253.76%-9.36%-8.82%8/12/2025 (Estimated)
Warby Parker Inc. stock logo
WRBY
Warby Parker
-$20.39M-$0.12N/A218.92N/A-1.79%-2.48%-1.29%8/6/2025 (Estimated)

Latest WEDXF, NVCR, CNMD, and WRBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/14/2025Q1 2025
Westaim Corp. stock logo
WEDXF
Westaim
-$0.0316-$0.34-$0.3084-$0.34$1.34 million($4.70) million
4/30/2025Q1 2025
CONMED Corporation stock logo
CNMD
CONMED
$0.81$0.95+$0.14$0.19$313.38 million$321.26 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CONMED Corporation stock logo
CNMD
CONMED
$0.801.54%N/A21.05%N/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Westaim Corp. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A
Warby Parker Inc. stock logo
WRBY
Warby Parker
N/AN/AN/AN/AN/A

Latest WEDXF, NVCR, CNMD, and WRBY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/21/2025
CONMED Corporation stock logo
CNMD
CONMED
quarterly$0.201.34%6/13/20256/13/20257/3/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CONMED Corporation stock logo
CNMD
CONMED
0.91
2.26
1.00
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41
Westaim Corp. stock logo
WEDXF
Westaim
N/A
11.40
11.40
Warby Parker Inc. stock logo
WRBY
Warby Parker
N/A
2.70
2.30

Institutional Ownership

CompanyInstitutional Ownership
CONMED Corporation stock logo
CNMD
CONMED
N/A
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Westaim Corp. stock logo
WEDXF
Westaim
N/A
Warby Parker Inc. stock logo
WRBY
Warby Parker
93.24%

Insider Ownership

CompanyInsider Ownership
CONMED Corporation stock logo
CNMD
CONMED
3.10%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Westaim Corp. stock logo
WEDXF
Westaim
4.21%
Warby Parker Inc. stock logo
WRBY
Warby Parker
18.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
CONMED Corporation stock logo
CNMD
CONMED
3,90030.94 million29.98 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable
Westaim Corp. stock logo
WEDXF
Westaim
733.56 million32.14 millionNot Optionable
Warby Parker Inc. stock logo
WRBY
Warby Parker
3,780104.50 million85.44 millionOptionable

Recent News About These Companies

Reviewing Warby Parker (WRBY) & Its Competitors
Warby Parker (WRBY) versus Its Rivals Financial Survey

New MarketBeat Followers Over Time

Media Sentiment Over Time

CONMED stock logo

CONMED NYSE:CNMD

$52.01 -0.33 (-0.63%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$52.36 +0.36 (+0.68%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$18.00 +0.90 (+5.26%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$17.78 -0.22 (-1.22%)
As of 05:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Westaim stock logo

Westaim OTCMKTS:WEDXF

$22.59 +0.04 (+0.18%)
As of 06/27/2025 02:35 PM Eastern

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.

Warby Parker stock logo

Warby Parker NYSE:WRBY

$21.89 +0.41 (+1.92%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$21.92 +0.03 (+0.13%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.